详情页 - 河北大学附属医院知识库

资源类型：

文章类型：

作者：

Shi, Yuankai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] * ; Chen, Gongyan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Wang, Xiang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Liu, Yunpeng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Wu, Lin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Hao, Yanrong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Liu, Chunling[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Zhu, Shuyang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Zhang, Xiaodong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Li, Yuping[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Liu, Jiwei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Cao, Lejie[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Cheng, Ying[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Zhao, Hui[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Zhang, Shucai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Zang, Ai-min[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20]

; Cui, Jiuwei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Feng, Jian[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Yang, Nong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Hu, Jie[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ;

机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China [2]Harbin Med Univ Canc Hosp, Dept Med Oncol, Harbin, Peoples R China [3]Xuzhou Cent Hosp, Dept Med Oncol, Xuzhou, Jiangsu, Peoples R China [4]First Hosp China Med Univ, Dept Med Oncol, Shenyang, Peoples R China [5]Hunan Canc Hosp, Dept Thorac Med, Changsha, Peoples R China [6]Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Med Oncol, Nanning, Peoples R China [7]Canc Hosp Xinjiang Med Univ, Dept Pulm Med, Urumqi, Peoples R China [8]Affiliated Hosp Xuzhou Med Coll, Dept Resp Med, Xuzhou, Jiangsu, Peoples R China [9]Canc Hosp Nantong, Dept Med Oncol, Nantong, Peoples R China [10]Wenzhou Med Univ, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Wenzhou, Peoples R China [11]Dalian Med Univ, Affiliated Hosp 1, Dept Oncol, Dalian, Peoples R China [12]USTC, Affiliated Hosp 1, Dept Resp Med, Hefei, Peoples R China [13]Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China [14]Second Hosp Anhui Univ, Dept Resp Med, Hefei, Peoples R China [15]Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Oncol Inst, Dept Med Oncol, Beijing, Peoples R China [16]Affiliated Hosp Hebei Univ,Sch Clin Med,Dept Med Oncol,Baoding,Peoples R China [17]Jilin Univ, Bethune Hosp 1, Dept Med Oncol, Changchun, Peoples R China [18]Affiliated Hosp Nantong Univ, Dept Resp Med, Nantong, Peoples R China [19]Hunan Canc Hosp, Dept Med Oncol, Lung Canc & Gastrointestinal Unit, Changsha, Peoples R China [20]Shanghai Allist Pharmaceut Technol Co Ltd, Shanghai, Peoples R China

出处：

DOI：

ISSN：

基金：

语种：

WOS：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2023]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China [2]Harbin Med Univ Canc Hosp, Dept Med Oncol, Harbin, Peoples R China [3]Xuzhou Cent Hosp, Dept Med Oncol, Xuzhou, Jiangsu, Peoples R China [4]First Hosp China Med Univ, Dept Med Oncol, Shenyang, Peoples R China [5]Hunan Canc Hosp, Dept Thorac Med, Changsha, Peoples R China [6]Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Med Oncol, Nanning, Peoples R China [7]Canc Hosp Xinjiang Med Univ, Dept Pulm Med, Urumqi, Peoples R China [8]Affiliated Hosp Xuzhou Med Coll, Dept Resp Med, Xuzhou, Jiangsu, Peoples R China [9]Canc Hosp Nantong, Dept Med Oncol, Nantong, Peoples R China [10]Wenzhou Med Univ, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Wenzhou, Peoples R China [11]Dalian Med Univ, Affiliated Hosp 1, Dept Oncol, Dalian, Peoples R China [12]USTC, Affiliated Hosp 1, Dept Resp Med, Hefei, Peoples R China [13]Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China [14]Second Hosp Anhui Univ, Dept Resp Med, Hefei, Peoples R China [15]Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Oncol Inst, Dept Med Oncol, Beijing, Peoples R China [16]Affiliated Hosp Hebei Univ,Sch Clin Med,Dept Med Oncol,Baoding,Peoples R China [17]Jilin Univ, Bethune Hosp 1, Dept Med Oncol, Changchun, Peoples R China [18]Affiliated Hosp Nantong Univ, Dept Resp Med, Nantong, Peoples R China [19]Hunan Canc Hosp, Dept Med Oncol, Lung Canc & Gastrointestinal Unit, Changsha, Peoples R China [20]Shanghai Allist Pharmaceut Technol Co Ltd, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study

文献详情